Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript
Arrowhead PharmaceuticalsArrowhead Pharmaceuticals(US:ARWR) Seeking Alpha·2026-01-06 20:18

Core Insights - Arrowhead Pharmaceuticals is presenting interim results from two obesity candidates, ARO-INHBE and ARO-ALK7, during a virtual KOL event [2]. Group 1 - The company is excited to share the first interim results from its obesity candidates [2]. - An external expert, Dr. Carel Le Roux, will provide insights on the findings related to obesity and metabolic diseases [3].